JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

5.54 -4.15

Overview

Share price change

24h

Current

Min

5.41

Max

5.94

Key metrics

By Trading Economics

Income

-24M

-202M

Sales

10M

15M

Profit margin

-1,373.259

Employees

800

EBITDA

-26M

-191M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+7.76% upside

Market Stats

By TradingEconomics

Market Cap

419M

2.7B

Previous open

9.69

Previous close

5.54

News Sentiment

By Acuity

50%

50%

176 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 sie 2025, 23:11 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 sie 2025, 22:45 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 sie 2025, 22:39 UTC

Earnings

Great-West Lifeco Logs Lower 2Q Profit

5 sie 2025, 21:32 UTC

Earnings

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 sie 2025, 23:48 UTC

Market Talk

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 sie 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 sie 2025, 23:19 UTC

Market Talk

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 sie 2025, 23:03 UTC

Market Talk
Earnings

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 sie 2025, 22:22 UTC

Earnings

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 sie 2025, 22:21 UTC

Earnings

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 sie 2025, 22:20 UTC

Earnings

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 sie 2025, 22:18 UTC

Earnings

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 sie 2025, 22:17 UTC

Earnings

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 sie 2025, 22:17 UTC

Earnings

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 sie 2025, 22:16 UTC

Earnings

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 sie 2025, 22:16 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 sie 2025, 22:15 UTC

Earnings

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 sie 2025, 22:13 UTC

Earnings

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 sie 2025, 22:13 UTC

Earnings

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 sie 2025, 22:12 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 sie 2025, 22:12 UTC

Earnings

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 sie 2025, 21:58 UTC

Earnings

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 sie 2025, 21:30 UTC

Earnings

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 sie 2025, 21:26 UTC

Earnings

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 sie 2025, 21:23 UTC

Earnings

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 sie 2025, 21:17 UTC

Earnings

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

7.76% upside

12 Months Forecast

Average 6.25 USD  7.76%

High 8 USD

Low 4 USD

Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

1

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

176 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.